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Objective: The aims of this cross-sectional study were to investigate the usefulness of using an 
Internet survey of patients with fibromyalgia in order to obtain information concerning symptoms 
and functionality and identify clusters of clinical features that can distinguish patient subsets.
Methods: An Internet website has been used to collect data. Fibromyalgia Impact Question-
naire Revised version, self-administered Fibromyalgia Activity Score, and Self-Administered 
Pain Scale were used as questionnaires. Hierarchical agglomerative clustering was applied to 
the data obtained in order to identify symptoms and functional-based subgroups.
Results: Three hundred and fifty-three patients completed the study (85.3% women). The 
highest scored items were those related to sleep quality, fatigue/energy, pain, stiffness, degree 
of tenderness, balance problems, and environmental sensitivity. A high proportion of patients 
reported pain in the neck (81.4%), upper back (70.1%), and lower back (83.2%). A three-cluster 
solution best fitted the data. The variables were significantly different (P,0.0001) among the 
three clusters: cluster 1 (117 patients) reflected the lowest average scores across all symptoms, 
cluster 3 (116 patients) the highest scores, and cluster 2 (120 patients) captured moderate 
symptom levels, with low depression and anxiety.
Conclusion: Three subgroups of fibromyalgia samples in a large cohort of patients have been 
identified by using an Internet survey. This approach could provide rationale to support the study 
of individualized clinical evaluation and may be used to identify optimal treatment strategies.
Keywords: fibromyalgia, Internet, FIQR, FAS, cluster analysis, SAPS, pain
Introduction
Fibromyalgia (FM) is a chronic heterogeneous syndrome that affects ∼2%–3% of the 
general population.1–3 Its primary symptom is chronic, widespread pain associated 
with generalized tenderness on light palpation. Many patients report a multitude of 
additional complaints and symptoms,4 including fatigue, exhaustibility and stiffness, 
and impaired concentration and memory (a complaint that is increasingly recognized 
as an independent symptom, namely, “fibrofog” or “dyscognition”, according to medi-
cal literature).5 The combinations and severity of symptoms may vary from patient to 
patient, and this makes it difficult to understand the disease and the development of 
appropriate treatment strategies.6 However, stratifying patients by cluster analysis into 
more homogeneous subgroups on the basis of their patient-relevant clinical features 
may help to overcome these limitations.7–14 Cluster analysis allows to identify clinical 
features and quantifies the importance of each cluster.15,16
A comprehensive assessment of main symptoms and the evaluation of the impact 
on the multidimensional aspects of function should be a routine part of patient care 
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in FM. Patient-reported outcomes (PROs) are playing an 
increasingly significant role in the evaluation of symptoms, 
health-related quality of life, and medical compliance.17 The 
Fibromyalgia Impact Questionnaire Revised version (FIQR) 
is currently the recommended tool for assessing function 
and health-related quality of life in patients with FM. FIQR 
assesses six domains (pain, tenderness, fatigue, stiffness, 
multidimensional function, and sleep) identified as core 
dimensions by Outcome Measures in Rheumatology Clinical 
Trials.18 Psychometric properties of FIQR (ie, rating scale 
functioning, internal construct validity, reliability indices, 
and dimensionality) have been validated.19,20 Routine PROs 
collection can be facilitated by using more advanced inter-
active computer technologies such as Internet-based home 
telemonitoring and can support a transition from institution 
to patient-centered applications.21–26
The aims of this cross-sectional study were to investigate 
the usefulness of an Internet-based national survey of patients 
with FM in order to obtain information concerning symptoms 
and functionality and to identify clusters of symptoms that 
helps to distinguish patient subsets.
Methods
Study population
The participants were selected from a large database of 
patients with FM referring to the Rheumatology Department 
of the Polytechnic University of Marche in Jesi (Ancona, 
Italy), the Internal Medicine and Rheumatology Unit of 
Parma Hospital, and the Rheumatology Unit of “L. Sacco” 
University Hospital in Milan (Italy). The following subjects 
have been excluded from the study: those affected by cardio-
vascular disease, moderate-to-severe chronic lung disease, 
uncontrolled hypertension, uncontrolled thyroid disturbances, 
inflammatory rheumatic conditions (ie, rheumatoid arthritis, 
systemic lupus erythematosus, and other connective tissue 
diseases), and/or psychoses or active suicidal ideation. A total 
of 496 patients have been screened, of which 143 refused to 
participate. The remaining 353 patients satisfied the Ameri-
can College of Rheumatology classification criteria for FM.27 
All patients have provided written informed consent, and 
the study was approved by the hospital Ethics Committee 
(Comitato Unico Regionale - ASUR Marche).
Internet-based PROs
The patients logged into the website (http://www.fibromi-
algiaitalia.it) developed for the present study. During the 
first login to the website, each patient was asked to provide 
consent and to complete the questionnaires. The questions 
were displayed using radio buttons. Each question had to be 
completed before the software continued to the following 
page. During the first visit, each patient has received a secure 
username/password combination in order to have access to 
the website and a brief training on the use of FIQR19 and the 
self-administered Fibromyalgia Activity Score (FAS)28 ques-
tionnaires. The FIQR was developed by Burckhardt et al29 in 
an attempt to address the limitations of the original FIQ.29 
The Italian version of FIQ20 is composed of 21 items that 
are rated using an 11-point numerical scale (0–10, with 10 
being the worst) and cover three domains: physical function, 
overall impact, and symptoms over the previous 7 days. The 
total score for the 9-item “function domain” (range: 0–90) 
is divided by three, the total score for the 2-item “overall 
impact domain” (range: 0–20) is divided by one, and the total 
score for the 10-item “symptom domain” (range: 0–100) is 
divided by two. The global score is given by the sum of the 
scores of the three domains (range: 0–100). FM is classified 
as mild (from 0 to 38), moderate (from 39 to 58), or severe 
(from 59 to 100).30 The FAS is a valid, reliable, and responsive 
 disease-specific composite measure for patients with FM.30 
The FAS index combines scores related to fatigue (range: 
0–10) and the quality of sleep (range: 0–10) and scores 
obtained by the Self-Administered Pain Scale (SAPS) in 
order to provide a single measure of disease activity (range: 
0–10). The SAPS asks patients to classify pain in 16 non-
articular sites (0 =none, 1 =mild, 2 =moderate, 3 =severe), 
and the final total score of 0–48 is transformed into a scale of 
0–10. At the end of the study, the electronically collected raw 
data were extracted as anonymous. The database was com-
pleted by the demographic characteristics of the patients.
Statistical analysis
The descriptive statistics of the continuous variables are given 
as mean values ± standard deviation and median values with 
their 25th to 75th percentiles, and those of the categorical 
variables as absolute numbers and percentages. The number 
of clusters was chosen by examining the dendrogram and con-
sidering clinical interpretability and usefulness. The variables 
of interest in the clusters were subsequently compared using 
analysis of variance followed by between-cluster pairwise 
comparisons with Bonferroni adjustment to a significance 
level of 0.05. Analysis of variance was also used to compare 
the behavior of the measured clinical subscales of the FIQR 
in the defined FM subgroups. The level of significance for 
all of the tests was 5%. The data were analyzed using the 
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Statistical Package for Social Sciences, Windows release 
11.0 (SPSS Inc., Chicago, IL, USA), and MedCalc, version 
12.7.0 (Mariakerke, Belgium).
Results
Demographic characteristics
Table 1 shows the demographic characteristics of the 353 
responders (85.3% women). Mean age of responders was 
50.9 years, 60.8% were married and only 24.1% had a high 
school/university education. The mean duration of pain was 
4.7 years (range: 1–18 years). Patients were moderately over-
weight as their mean body mass index was 28.5 (body mass 
index of .25 and .30 were found in 40% and 7% of cases, 
respectively). No significant differences of demographic 
characteristics were observed between patients who agreed 
to participate in the study and those who did not.
Descriptive statistics
Table 2 shows FIQR item, subscale, and total scores. The 
highest scoring items (those with the greatest disease impact) 
were the following symptoms related: sleep quality (FIQR15), 
Table 1 Participant demographics (n=353)
Characteristics Mean (SD) or n (%)
Sex
  Female, n (%) 301 (85.3)
  Male, n (%) 52 (14.7)
Age, years (SD) 50.9 (11.3)
Disease duration, years, mean (SD) 4.7 (3.8)
Education
  Primary school, n (%) 38 (10.7)
  Secondary school, n (%) 230 (65.2)
  High school/university, n (%) 85 (24.1)
Employment status
  employed, n (%) 182 (51.5)
  Work disabled, n (%) 31 (8.8)
   Other (student, full-time homemaker,  
other), n (%)
79 (22.4)
  Unemployed, n (%) 61 (17.3)
Marital status
  Married, n (%) 215 (60.8)
  Divorced/separated, n (%) 49 (13.8)
  Single, n (%) 64 (18.3)
  Widowed, n (%) 25 (7.1)
BMI, kg/m2, mean (SD) 28.5 (5.2)
Abbreviations: BMI, body mass index; SD, standard deviation.
Table 2 Scores obtained on the FIQR (mean and median values, SDs and 95% confidence intervals for each item, subdimensions and 
total score of the FIQR, and for total score of the FAS) by the study patients (n=353)
Item  
number
Item description Mean SD Median 25–75th 
Percentiles
1 Brush or comb hair 3.82 2.34 4.00 2.00–5.00
2 Walk continuously for 20 minutes 3.78 2.84 3.00 2.00–6.00
3 Prepare a homemade meal 3.46 2.39 3.00 2.00–5.00
4 Vacuum, scrub, or sweep floors 4.87 2.85 5.00 3.00–7.00
5 Lift and carry a bag full of groceries 5.18 2.97 5.00 3.00–8.00
6 Climb one flight of stairs 4.72 2.32 5.00 3.00–7.00
7 Change bed sheets 4.72 2.64 5.00 3.00–7.00
8 Sit in a chair for 45 minutes 4.82 2.79 5.00 3.00–7.00
9 Go shopping for groceries 4.23 2.77 4.00 2.00–7.00
FIQR function subtotal 12.36 6.81 11.70 6.30–17.70
10 Cannot achieve goals 4.49 2.69 5.00 2.00–7.00
11 Feel overwhelmed 4.67 2.73 5.00 2.00–7.00
FIQR overall impact subtotal 9.16 5.64 8.00 4.00–13.00
12 Pain rating 5.69 2.32 6.00 4.00–8.00
13 Fatigue rating 6.04 2.54 6.00 4.00–8.00
14 Stiffness rating 5.64 2.45 6.00 4.00–8.00
15 Sleep quality 6.18 2.57 6.00 4.00–8.00
16 Depression level 4.94 2.49 5.00 3.00–7.00
17 Memory problems 4.90 2.33 5.00 3.00–7.00
18 Anxiety level 4.99 2.46 4.00 3.00–7.00
19 Tenderness level 5.42 2.42 6.00 4.00–7.00
20 Balance problems 5.33 2.01 5.50 4.00–7.00
21 environmental sensitivity 5.32 2.48 6.00 3.00–7.00
FIQR symptoms subtotal 26.76 8.78 27.50 20.50–33.50
FIQR total score 48.28 19.20 47.65 32.30–63.50
Abbreviations: FAS, Fibromyalgia Activity Score; FIQR, Fibromyalgia Impact Questionnaire Revised version; SD, standard deviation.
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fatigue/energy (FIQR13), pain (FIQR12), stiffness (FIQR14), 
tenderness (FIQR19), balance problems (FIQR20), and 
environmental sensitivity (FIQR21). The lowest scored items 
included functional activities such as brushing/combing hair 
(FIQR1), preparing a home-made meal (FIQR3), walking 
continuously for 20 minutes (FIQR2), shopping for groceries 
(FIQR9), and changing bed sheets (FIQR7).
Figure 1 shows the distribution of the FIQR scores. The 
impact of the disease on functional domains such as personal 
care (FIQR1) and activities of daily living (FIQR3, FIQR4, 
FIQR5, FIQR7, and FIQR9) was greater among women, but 
the differences were not significant. Similarly, pain (FIQR12), 
fatigue (FIQR13), rigidity (FIQR14), and sleep quality 
(FIQR15) were not significantly associated with sex.
SAPS was used to assess the presence of pain in 16 body 
sites. A high proportion of patients reported pain in the 
neck (81.4%), upper back (70.1%), and lower back (83.2%) 
( Figure 2). There was no difference between sexes in relation 
to any of the sites.
Cluster analysis
It was used hierarchical agglomerative clustering of the 21 
subscales of the FIQR, respectively, accounting for 33.1%, 
34%, and 32.9% of the sample. The three-cluster solution 
distinguished three broad levels of severity. Clusters 1 and 3 
correspond to the lowest and highest average scores, respec-
tively, and cluster 2 to lower levels of depression, anxiety, 
and less severe memory problems compared to the other 
scales of the FIQR (Table 3 and Figure 3). The pairwise 
comparisons showed significant differences between each 
cluster for all but a few symptoms. Clusters 2 and 3 were 
not significantly different in terms of walking continuously 
for 20 minutes (P=0.11) or lifting and carrying a bag full of 
groceries (P=0.21) (Figure 3).
Discussion
Over the last few years, the ongoing evolution of computer 
software and technology has greatly improved the ability to 
collect PROs data. One major advantage of computerized 
questionnaires is to collect good-quality data without any 
missing or problematic responses commonly found by using 
paper questionnaires.21–25,31 Online surveys enable respon-
dents to answer questionnaires according to their preferences 
(eg, ways and connection times) while connected to the 
Internet browser.22–24
Our questionnaire was completed by 353 patients with 
FM, and demographic features of respondents were similar to 
previous epidemiologic studies and surveys.17,28,32–34 Respon-
dents have reported several symptoms mainly including poor 
quality sleeping, fatigue/lack of energy, pain, stiffness, tender-
FIQR-14
FIQR-15
FIQR-16
FIQR-17
FIQR-18
FIQR-19
FIQR-20
FIQR-21
FIQR-13
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FIQR overall impact
(items 10 and 11)
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0
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7
Figure 1 Spydergrams of the FIQR domains.
Notes: The domain scores are plotted from 0 (best, at the center) to 10 (worst, at the outside).
Abbreviation: FIQR, Fibromyalgia Impact Questionnaire Revised version.
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Left LeftRight Right
176 (52.7%)
134 (40.1%)
152 (45.5%)
193 (57.8%)
197 (58.9%)
186 (55.7%)
174 (52.1%)
199 (59.6%)
272 (81.4%)
234 (70.1%)
189 (56.6%)
165 (48.9%)
278 (83.2%)
175 (52.4%)
160 (47.9%)
160 (47.9%)
Figure 2 Pain by location expressed in terms of percentage (%) as revealed by the Self-Administered Pain Scale.
Note: Data are presented as n (%).
Table 3 Subgrouping of fibromyalgia samples based on scores obtained on the FIQR (mean and standard deviations) for each item, 
subdimensions and total score
Item no Item description Cluster 1 (n=117) Cluster 2 (n=120) Cluster 3 (n=116) F-ratio
Mean SD Mean SD Mean SD
1 Brush or comb hair 1.64 1.05 4.14 1.95 5.70 1.81 178.90
2 Walk continuously for 20 minutes 1.75 1.54 4.22 3.02 5.38 2.44 67.51
3 Prepare a homemade meal 1.44 1.09 3.30 1.85 5.69 1.90 192.73
4 Vacuum, scrub, or sweep floors 2.74 1.40 4.97 3.03 6.94 2.11 98.36
5 Lift and carry a bag full of groceries 3.16 2.32 5.45 2.95 6.95 2.26 65.83
6 Climb one flight of stairs 2.39 1.46 5.28 1.62 6.51 1.59 213.56
7 Change bed sheets 2.73 2.17 4.53 1.99 6.94 1.86 126.76
8 Sit in a chair for 45 minutes 2.85 2.18 4.80 2.60 6.85 1.99 88.64
9 Go shopping for groceries 1.61 1.37 4.39 1.98 6.74 2.05 227.56
FIQR physical function 6.50 3.64 13.62 6.06 17.02 5.65 123.37
10 Cannot achieve goals 2.04 1.78 4.54 1.93 6.94 1.67 216.11
11 Feel overwhelmed 1.87 1.56 5.13 1.86 7.05 1.71 271.60
FIQR overall impact 4.00 3.93 10.13 4.96 11.35 4.97 84.44
12 Pain rating 3.13 1.43 6.35 1.47 7.62 1.18 343.82
13 Fatigue rating 3.60 1.83 6.09 1.56 8.49 1.34 287.57
14 Stiffness rating 3.16 1.50 6.01 1.67 7.79 1.46 276.56
15 Sleep quality 3.59 1.86 6.55 1.51 8.44 1.52 270.29
16 Depression level 2.55 1.39 4.46 0.95 7.87 1.21 589.57
17 Memory problems 2.66 1.35 4.55 1.07 7.54 1.18 487.14
18 Anxiety level 3.01 1.48 4.16 0.93 7.86 1.58 401.85
19 Tenderness level 3.30 2.08 5.85 1.85 7.13 1.50 137.22
20 Balance problems 3.34 1.42 5.72 1.22 6.96 1.37 219.63
21 environmental sensitivity 2.66 1.64 6.00 1.39 7.31 1.59 281.67
FIQR symptoms 18.06 5.94 28.12 6.10 34.19 5.21 233.51
FIQR total 28.57 10.31 51.88 14.77 62.57 13.44 210.32
Notes: Cluster 1 reflecting the lowest average levels across all symptoms, cluster 3 reflecting the highest average levels across all symptoms, and cluster 2 capturing 
moderate symptom levels with lower levels of depression, anxiety, and memory problems.
Abbreviations: FIQR, Fibromyalgia Impact Questionnaire Revised version; SD, standard deviation; no, number.
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ness, and increasing environmental sensitivity. There were no 
significant differences between sexes in these domains. The 
tendency for women to have higher scores in some domains 
(eg, brushing/combing hair, preparing home-made meals, 
vacuum cleaning, scrubbing/sweeping floors, or shopping) 
seems related to the fact that those daily activities are peculiar 
to female sex.
Cluster analysis has revealed three distinctive sub-
groups of symptoms: cluster 1 lowest mean total FIQR and 
FIQR scores (ranging from 0 to 39);35 cluster 2 moder-
ate symptoms and mild levels of cognitive/psychological 
impairment (scores ranging from 39 to 59); and cluster 
3 severe symptoms (scores ranging from 59 to 100). Our 
findings have some similarities with results from previous 
cluster analyses in patients with FM. Vincent et al15 found 
that a four-cluster solution best fit their results: clusters 1 
and 4 correspond to the lowest and highest scores among 
all symptoms and clusters 2 and 3 intermediate levels of 
anxiety and depression, with cluster 2 having lower levels 
of depression and anxiety than cluster 3, despite higher 
levels of pain. Similarly, the cluster analysis of Wilson 
et al36 identified four clusters: cluster 1 had high scores 
9
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Figure 3 Cluster profiles.
Notes: Cluster 1 (n=117, red line) showed generally low symptom intensity; cluster 2 (n=120, blue line) was characterized by moderate symptoms and low cognitive/
psychological domain scores; cluster 3 (n=116, gray line) showed the least control over pain, considerable tenderness, high symptom levels, and considerable cognitive/
psychological problems.
Abbreviation: FIQR, Fibromyalgia Impact Questionnaire Revised version.
in all three domains, cluster 2 had moderate scores in the 
two physical symptoms domains and high cognitive/psy-
chological symptom scores, cluster 3 had moderate scores 
in the two physical symptoms domains and low cognitive/
psychological symptoms scores, and cluster 4 had low 
scores in all symptoms domains. Clusters 2 and 3 were 
therefore distinguished by differences in the severity of 
depression and anxiety, which is also consistent with the 
findings of Giesecke et al.8 In this study, the authors have 
identified three patient-subsets mainly on the basis of dif-
ferences in pain and psycho pathology as follows: first one 
characterized by moderate levels of mood, catastrophizing 
and perceived pain control, and low levels of tenderness; 
second one characterized by high degree of mental impair-
ment, highest catastrophizing subscales and severe pain; 
third one characterized by normal mood ratings, very low 
levels of catastrophizing and the highest level of perceived 
pain control even though they showed extreme tenderness 
when evoked pain was tested. However, our findings are 
not directly comparable with those of these studies8,15,36 
because they used measurements of experimental pain and 
some variables were not included in our study.
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De Souza et al13 also highlighted anxiety and depression 
as differentiating factors in their two-cluster model based on 
the FIQ: both FM subgroups showed hyperalgesic responses to 
experimental pain, but type I was characterized by the lowest 
levels of anxiety, depression, and morning tiredness and type 
II by high levels of pain, fatigue, morning tiredness, stiffness, 
anxiety, and depression. Similarly, Docampo et al37 have identi-
fied three subgroups in a series of 1,446 Spanish patients. One 
with low symptom scores and few comorbidities; second one 
with high symptom scores and multiple comorbidities; and third 
one with high symptom scores but few comorbidities. Psycho-
logical and cognitive impairments (such as memory deficits) are 
associated with a wide variety of pain conditions.38–40 The fact 
that these clinical features seem to be more severe in patients 
with FM suggested that a group of alterations in a disorder may 
enhance the magnitude of specific symptoms such as pain. Wil-
liams et al41 found that the domains of mood and fatigue were 
closely associated with perceived dyscognitions in FM, whereas 
pain was uniquely associated with perceived language deficits 
and, unexpectedly, was not related to attention or concentration. 
In line with this, our findings indicate that memory problems 
and psychological symptoms (anxiety and depression) were 
not associated with pain intensity in cluster 2.
Our study has some methodological limitations. First 
of all, the use of the Internet browser was associated with 
various socioeconomic and demographic factors, including 
age, sex, location, and education, and users could not to be 
representative of target population. However, Internet-based 
assessments have been accepted by a sizeable percentage 
(71.2%) of the eligible patients. Second, we did not select 
patients on the basis of their ongoing pharmacological 
therapy, although this is an important factor that may mediate 
dyscognition in FM. It is extremely rare to find a diagnosed 
subject who is not taking continuous doses of antidepressants 
(eg, amitriptyline, duloxetine), antiepileptic drugs (gabapen-
tin, pregabalin), or strong analgesics (tramadol, opioids),42,43 
and it is entirely reasonable to expect that medications may 
reduce cognitive test performances,44 thus making difficult 
to distinguish which deficits may be attributable to FM and 
which to drugs. A final limitation is that the analysis was 
based on a population of adults from a relatively limited 
geographical area in central and northern Italy.
Conclusion
We have identified three subgroups of FM samples in a 
large cohort of FM using an Internet survey. Cluster 1 had 
the lowest mean total FIQR score, which also fell within 
the mild symptom severity range of the FIQR, whereas 
cluster 3 was characterized by severe symptoms, cluster 2 
captured moderate symptoms with mild levels of cognitive/
psychological symptoms. Web surveys allow rapid updating 
of questionnaire content and question ordering according to 
user responses and could provide rationale to support the 
study of individualized clinical evaluation and may be used 
to identify optimal treatment strategies.
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